Shah Pritesh's Form 4 filing
NovoCure Ltd (NVCR) · filed Mar 9, 2022
- Accession no.
- 0001645113-22-000030
- Filed
- Mar 9, 2022
- Trade date
- Mar 7-8, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $542.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Shah PriteshCIK 0001744884 | Officer (Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 7, 2022 | Ordinary Shares | SSaleDisposed | −5,294 | $69.55 | −$368,197.7 | 84,389 | Direct | |
| Mar 8, 2022 | Ordinary Shares | SSaleDisposed | −2,481 | $70.10 | −$173,918.1 | 81,908 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.